Hypofractionated radiotherapy for 45 cancer patients with hepatic metastasis
Zhao Ruizhi, Xiao Jianping, Zhang Hongmei, Ma Yuchao, Yang Siran, Liu Qingfeng, Zhang Ye, Wang Kai, Deng Lei, Bi Nan, Wang Wenqing, Yi Junlin, Li Yexiong
Department of Radiation Oncology (Zhao RZ,Xiao JP,Ma YC,Yang SR,Liu QF,Zhang Ye,Wang K,Deng L,Bi N,Wang WQ,Yi JL,Li YX),Department of Radiology (Zhang HM),National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
Abstract：Objectives To evaluate the clinical efficacy and safety of hypofractionated radiotherapy for cancer patients with hepatic metastases. Methods From May 2007 to November 2016,45 patients (male:female=20:25) with inoperable hepatic metastases were enrolled in this investigation. The median age was 58 years old (range:25-83).The median Karnofsky performance score (KPS) was 80.Primary colorectal cancer was detected in 14 patients,primary breast cancer in 9 and primary lung cancer in 6 cases. Twenty-one patients had extrahepatic metastases. A total of 52 lesions were treated. Thirty-four cases received radiotherapy for one single lesion. The fractional dose was 45 Gy/3 fractions and 60 Gy/10-15 fractions. The median gross tumor volume (GTV) was 10.1 cm3(0.3-175.2 cm3) and 29.8 cm3(5.0-209.6 cm3) for planning target volume (PTV).Seventeen CT images were fused with MRI and IMRT was adopted in 43 cases. The median dose of PTV was 60 Gy (40-60 Gy) and 90 Gy (60-132 Gy) for bioequivalent dose (BED). Results The median follow-up time was 23.5 months and the median survival time was 26.0 months (95%CI:21.4-30.6 months).The 1-year local control (LC),disease-free survival (DFS) and overall survival (OS) were 94%,27% and 91%,respectively. Six cases died of liver metastases and abnormal liver function. Conclusion Hypofractionated radiotherapy is an efficacious and safe local treatment for inoperable hepatic metastases.
Zhao Ruizhi,Xiao Jianping,Zhang Hongmei et al. Hypofractionated radiotherapy for 45 cancer patients with hepatic metastasis[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1061-1065.
[1] Foster JH.Treatment of metastatic disease of the liver:a skeptic′s view[J].Semin Liver Dis,1984,4(2):170-179. [2] Bengmark S,Hafstrom L.The natural history of primary and secondary malignant tumors of the liver. I.The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy[J].Cancer,1969,23(1):198-202. [3] de Brauw LM,van de Velde CJ,Bouwhuis-Hoogerwerf ML,et al. Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases[J].J Surg Oncol,1987,34(2):81-86. [4] Pawlik TM,Choti MA.Surgical therapy for colorectal metastases to the liver[J].J Gastrointest Surg,2007,11(8):1057-1077.DOI:10.1007/s11605-006-0061-3. [5] Hellman S,Weichselbaum RR.Oligometastases[J].J Clin Oncol,1995,13(1):8-10. [6] Kanas GP,Taylor A,Primrose JN,et al. Survival after liver resection in metastatic colorectal cancer:review and meta-analysis of prognostic factors[J].Clin Epidemiol,2012(4):283-301.DOI:10.2147/CLEP.S34285. [7] Pwint TP,Midgley R,Kerr DJ.Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver[J].Semin Oncol,2010,37(2):149-159.DOI:10.1053/j.seminoncol.2010.03.005. [8] Dawson LA,Normolle D,Balter JM,et al. Analysis of radiation-induced liver disease using the Lyman NTCP model[J].Int J Radiat Oncol Biol Phys,2002,53(4):810-821. [9] Goodman KA,Wiegner EA,Maturen KE,et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies[J].Int J Radiat Oncol Biol Phys,2010,78(2):486-493.DOI:10.1016/j.ijrobp.2009.08.020. [10] Scorsetti M,Comito T,Tozzi A,et al. Final results of a phase Ⅱ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer[J].J Cancer Res Clin Oncol,2015,141(3):543-553.DOI:10.1007/s00432-014-1833-x. [11] 张烨,肖建平,李晔雄,等.体部立体定向放射治疗肝转移瘤22例临床疗效[J].中华放射肿瘤学杂志,2010(2):135-138.DOI:10.3760/cma.j.issn.1004.4221.2010.02.014. Zhang Y,Xiao JP,Li YX,et al. Clinical efficacy of stereotactic radiotherapy in the treatment of 22 cases of hepatic metastatic tumors[J].Chin J Radiat Oncol,2010(2):135-138.DOI:10.3760/cma.j.issn.1004.4221.2010.02.014. [12] Rusthoven KE,Kavanagh BD,Cardenes H,et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for liver metastases[J].J Clin Oncol,2009,27(10):1572-1578.DOI:10.1200/JCO.2008.19.6329. [13] Aitken KL,Tait DM,Nutting CM,et al. Risk-adapted strategy partial liver irradiation for the treatment of large volume metastatic liver disease[J].Acta Oncol,2014,53(5):702-706.DOI:10.3109/0284186X.2013.8625. [14] Lee MT,Kim JJ,Dinniwell R,et al. Phase Ⅰ study of individualized stereotactic body radiotherapy of liver metastases[J].J Clin Oncol,2009,27(10):1585-1591.DOI:10.1200/JCO.2008.20.0600. [15] Chang DT,Swaminath A,Kozak M,et al. Stereotactic body radiotherapy for colorectal liver metastases:a pooled analysis[J].Cancer,2011,117(17):4060-4069.DOI:10.1002/cncr.25997. [16] Hoyer M,Roed H,Traberg HA,et al. Phase Ⅱ study on stereotactic body radiotherapy of colorectal metastases[J].Acta Oncol,2006,45(7):823-830.DOI:10.1080/02841860600904854. [17] de Vin T,Engels B,Gevaert T,et al. Stereotactic radiotherapy for oligometastatic cancer:a prognostic model for survival[J].Ann Oncol,2014,25(2):467-471.DOI:10.1093/annonc/mdt537. [18] Mendez RA,Wunderink W,Hussain SM,et al. Stereotactic body radiation therapy for primary and metastatic liver tumors:A single institution phase Ⅰ-Ⅱ study[J].Acta Oncol,2006,45(7):831-837.DOI:10.1080/028418606008979.
2018, Vol. 27 
